212 related articles for article (PubMed ID: 29021516)
1. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia.
Miyagi D; Chen WY; Chen BJ; Su YZ; Kuo CC; Karube K; Chuang SS
Cytopathology; 2020 Nov; 31(6):602-606. PubMed ID: 32681657
[No Abstract] [Full Text] [Related]
3. Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
SahBandar IN; Sy CB; van den Akker T; Kim D; Geyer JT; Chadburn A; Cesarman E; Inghirami G; Allan JN; Siddiqui MT; Ouseph MM
Pathobiology; 2023; 90(5):356-364. PubMed ID: 36996787
[TBL] [Abstract][Full Text] [Related]
4. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
Suyama T; Hagihara M; Matsui N; Irie R; Osamura Y; Sakai T; Watanabe S; Umemoto S; Miyao N
J Clin Exp Hematop; 2023 Mar; 63(1):43-48. PubMed ID: 36843069
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2018 Jul; 124(13):2740-2747. PubMed ID: 29723397
[TBL] [Abstract][Full Text] [Related]
7. HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.
Christe L; Veloza L; Gros L; Bisig B; Blum S; Hewer E; de Leval L
Diagn Cytopathol; 2022 Dec; 50(12):E351-E356. PubMed ID: 35916333
[TBL] [Abstract][Full Text] [Related]
8. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.
Satoh K; Morisawa S; Okuyama M; Nakae H
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479888
[TBL] [Abstract][Full Text] [Related]
9. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
Tiribelli M; Abruzzese E; Capodanno I; Sorà F; Trabacchi E; Iurlo A; Luciano L; Binotto G; Bonifacio M; Annunziata M; Crugnola M; Fanin R
Ann Hematol; 2019 Nov; 98(11):2609-2611. PubMed ID: 31529281
[No Abstract] [Full Text] [Related]
11. Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma.
Hayashino K; Meguri Y; Yukawa R; Komura A; Nakamura M; Yoshida C; Yamamoto K; Oda W; Imajo K
Int J Hematol; 2023 Jan; 117(1):137-142. PubMed ID: 36066839
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.
Skride A; Sablinskis M; Sablinskis K; Lesina K; Lejnieks A; Lejniece S
J Med Case Rep; 2017 Dec; 11(1):362. PubMed ID: 29287600
[TBL] [Abstract][Full Text] [Related]
13. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Hagihara M; Iriyama N; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Oncol Rep; 2016 Nov; 36(5):2976-2982. PubMed ID: 27665844
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
15. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.
Hughes TP; Laneuville P; Rousselot P; Snyder DS; Rea D; Shah NP; Paar D; Abruzzese E; Hochhaus A; Lipton JH; Cortes JE
Haematologica; 2019 Jan; 104(1):93-101. PubMed ID: 30093398
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
17. Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Aslan NA; Hıncal HO; Elver Ö; Erol V; Güler N
J Oncol Pharm Pract; 2023 Mar; 29(2):511-516. PubMed ID: 35821583
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
19. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Drug-Induced Organizing Pneumonia Caused by Dasatinib].
Sato M; Watanabe S; Aoki N; Asakawa K; Moriyama H; Oshima Y; Koya T; Okazuka K; Kikuchi T
Gan To Kagaku Ryoho; 2018 May; 45(5):851-854. PubMed ID: 30026450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
